Category Archives: healthcare
By Guest Blogger | Published: December 10, 2013
By Leela Barham. Collaboration seems to be ‘in’ thing and it’s set to continue in Europe with the European Medicines Agency (EMA) and EUnetHTA agreeing a three-year joint work plan.
By Guest Blogger | Published: November 26, 2013
U.S. Pharma in the Eye of the Obamacare Storm So, we’ve experienced two months of Obamacare. How is the U.S. pharmaceutical industry doing with this new program? I spent two weeks getting the opinions of several Rx representatives on their experience with Obamacare, as well as their thoughts on how it is impacting their marketing, sales, [...]
By Ben Comer | Published: November 25, 2013
FDA’s new Breakthrough Therapies designation sped Pharmacyclics/J&J’s ibrutinib (brand name: Imbruvica) through regulatory review in four months, based on Phase 2 studies. Pricing and access issues, though, may not get resolved so quickly.
By Guest Blogger | Published: November 22, 2013
The annual worldwide antibiotic awareness event—celebrated in Europe on November 15—generated some alarming statistics, some reassuring statements from official sources, and some expressions of urgency from drug developers. But it was perhaps most compellingly marked by a plangent call for better medicines from an unusual source. First, the statistics. Superbugs are on the way to a [...]
By Guest Blogger | Published: November 21, 2013
Waste to Taxpayers detected in Medicare Part D Plan, Poorer people are being prescribed more expensive branded drugs. Is that bad? According to a new investigation it is. And it is costing the taxpayers a shovel-load of money. And furthermore, it’s unnecessary. The failure of the government to track doctors who prescribe cheaper generics for their patients [...]